Reitan Colleen F 4

What Happened Colleen F. Reitan, a director of Alnylam Pharmaceuticals (ALNY), received equity awards on May 20, 2026 totaling 2,112 units: 671 restricted stock units (RSUs) and 1,441 derivative units, each granted at $0.00 (no cash paid). These are awards (not purchases or sales) and represent contingent rights to receive shares subject to vesting.

Key Details

• Transaction date: May 20, 2026; Form 4 filed May 22, 2026 (timely).
• Grants: 671 RSUs @ $0.00; 1,441 derivative units @ $0.00; total = 2,112 units; reported acquisition value = $0.
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes:
  • F1: The 671 RSUs represent contingent rights to one share each and vest in full on the earlier of the first anniversary of the grant or certain earlier retirement/resignation events (only if resignation/retirement occurs no more than 90 days before the first anniversary).
  • F2: The filing also describes vesting terms for a stock option (if applicable) that mirror the RSU vesting — vesting in full on the earlier of one year or qualifying retirement/resignation within the 90‑day window.
• Filing timeliness: Reported two days after the transaction date (within the typical Form 4 reporting window).

Context These awards are standard equity compensation for directors. RSUs and derivative units are contingent rights that convert to shares only after vesting; they do not represent an immediate purchase or sale and therefore are not a direct buy/sell signal. The vesting terms mean the shares are likely to convert to stock after roughly one year unless an eligible retirement/resignation accelerates vesting.